PRIMARY PERITONEAL CARCINOSARCOMA
Clinical trials for PRIMARY PERITONEAL CARCINOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL CARCINOSARCOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL CARCINOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine combo aims to outsmart recurrent ovarian cancer
Disease control Recruiting nowThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRalphaDC) with an immunotherapy drug (pembrolizumab). The goal is to safely boost the immune system to rec…
Matched conditions: PRIMARY PERITONEAL CARCINOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
New combo therapy aims to drain ovarian Cancer's fluid trap
Disease control Recruiting nowThis study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) works better than bevacizumab alone for recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup. About 60 adults w…
Matched conditions: PRIMARY PERITONEAL CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:59 UTC
-
New vaccine aims to keep ovarian cancer at bay
Disease control Recruiting nowThis study tests a vaccine made from a patient's own white blood cells, designed to train the immune system to attack ovarian cancer cells. It is for people with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the vaccine can …
Matched conditions: PRIMARY PERITONEAL CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:41 UTC